Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

BACKGROUND: Fluticasone furoate/vilanterol (FF/VI) is a novel, once-daily, inhaled corticosteroid/long-acting β(2)-agonist combination approved for the treatment of COPD and asthma. We compared the safety and efficacy of FF/VI and tiotropium (TIO) in subjects with moderate-to-severe COPD with greate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Int J Chron Obstruct Pulmon Dis
Hauptverfasser: Covelli, Henry, Pek, Bonavuth, Schenkenberger, Isabelle, Scott-Wilson, Catherine, Emmett, Amanda, Crim, Courtney
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2015
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694692/
https://ncbi.nlm.nih.gov/pubmed/26730183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S91407
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge